least 6 weeks, or confirmed partial response or complete response using RECIST was 64%. The median OS was 27 months. 27 Other Therapies for Patients With Non-Clear Cell Carcinomas Bevacizumab is a humanized monoclonal antibody that binds and
Search Results
Kidney Cancer, Version 2.2014
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar
Rationing Cancer Care: A Survey Among the Members of the German Society of Hematology and Oncology
Stefan W. Krause, Jan Schildmann, Christian Lotze, and Eva C. Winkler
given examples of treatments withheld on the grounds of unconvincing evidence and based on an unfavorable cost/benefit analysis were erlotinib, bevacizumab, and other antibodies ( Table 3 , Q5 and Q7). Typical examples for withholding treatments because
A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States
Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, and Ignacio Garrido-Laguna
these agents, novel therapies or combinations are needed. A recent phase II study met its primary endpoint by showing improved progression-free survival with the combination of TAS-102/bevacizumab compared with TAS-102 alone in patients with refractory
NCCN Task Force Report: mTOR Inhibition in Solid Tumors
Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen
as bevacizumab, sorafenib, or sunitinib, could complement the downstream antiangiogenic effect of mTOR inhibition. Various tyrosine kinase inhibitors could interrupt the activation of various upstream mTOR signaling pathways, thus complementing direct
Non–Small Cell Lung Cancer
David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Janis O’Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang, Miranda Hughes, and Kristina M. Gregory
. 118 , 119 Targeted Therapies: Specific targeted therapies have been developed for the treatment of advanced lung cancer. 120 , 121 Bevacizumab is a recombinant monoclonal antibody that blocks the vascular endothelial growth factor (VEGF). Erlotinib
Kidney Cancer
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder
, temsirolimus, everolimus, and bevacizumab in combination with interferon. Tumor histology and risk stratification of patients is important in targeted therapy selection. The most widely used model for risk stratification is the MSKCC model, 46 which
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
E. Gabriela Chiorean, Marco Del Chiaro, Margaret A. Tempero, Mokenge P. Malafa, Al B. Benson III, Dana B. Cardin, Jared A. Christensen, Vincent Chung, Brian Czito, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Christos Fountzilas, Evan S. Glazer, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Ashiq Masood, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Lorenzo Nardo, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Mark J. Truty, Charles Vollmer Jr, Robert A. Wolff, Brian M. Wolpin, Beth McCullough RN, Senem Lubin, and Susan D. Darlow
intestinal type ampullary cancer, all recommendations are derived from the NCCN Guidelines for Colon Cancer (available at NCCN.org ). Most of the recommendations are based on phase II/III, randomized data (FOLFOXIRI ± bevacizumab, 167 FOLFOX ± bevacizumab
Treating Triple-Negative Breast Cancer: Where Are We?
Aki Morikawa and Andrew D. Seidman
(response rate, 1.45; 95% CI, 1.25–1.68; P <.001). 44 The GeparSixto study evaluated the addition of carboplatin to paclitaxel and pegylated liposomal doxorubicin (plus bevacizumab in TNBC) in the neoadjuvant setting. 45 The addition of carboplatin was
Treatment of Non–Small Cell Lung Cancer in the Older Patient
Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria
believed that they have a broader therapeutic index and are potentially less toxic. 49 Two of these agents, erlotinib and bevacizumab, are currently approved by the FDA for the treatment of NSCLC. Erlotinib, a small molecule epidermal growth factor
Differential Radiographic Appearance of BRAF V600E–Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location
Chloe E. Atreya, Claire Greene, Ryan M. McWhirter, Nabia S. Ikram, I. Elaine Allen, Katherine Van Loon, Alan P. Venook, Benjamin M. Yeh, and Spencer C. Behr
prognosis in patients treated with conventional chemotherapy. 13 – 22 In the TRIBE and FIRE-3 studies, patients with BRAF wild-type tumors treated with FOLFIRI plus bevacizumab had a median overall survival (mOS) of 2 or more years, whereas mOS of